Title (en)

METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING DESMETHYLSELEGILINE

Title (de)

VERFAHREN UND ARZNEIMITTEL UNTER VERWENDUNG VON DESMETHYLSELEGILIN

Title (fr)

PROCEDES ET COMPOSITIONS PHARMACEUTIQUES UTILISANT DE LA DESMETHYLSELEGILINE

Publication

EP 0812188 A2 19971217 (EN)

Application

EP 96904573 A 19960111

Priority

- US 9601561 W 19960111
- US 37213995 A 19950113
- US 197995 P 19950731

Abstract (en)

[origin: CA2209892A1] Methods and pharmaceutical compositions for using the selegiline metabolite desmethylselegiline and stereoisomeric forms thereof. In particular, the present invention provides novel compositions and methods for using desmethylselegiline, and/or ent-desmethylselegiline, for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neural trauma and those due to immune system dysfunction. Desmethylselegiline, and/or entdesmethylselegiline, is either administered orally or by a route of administration which does not rely upon gastrointestinal absorption. Desmethylselegiline is the R-(-) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane and ent-desmethylselegiline is the S(+) enantiomer. Claimed compositions include both the R-(-) and S-(+) isomers as well as mixtures thereof. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.0015 mg/kg of body weight.

IPC 1-7

A61K 31/00

IPC 8 full level

A61K 31/137 (2006.01)

CPC (source: EP)

A61K 31/137 (2013.01)

Citation (search report)

See references of WO 9622068A2

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

AU 4864496 A 19960807; AU 695359 B2 19980813; CA 2209892 A1 19960725; CA 2209892 C 20020305; EP 0812188 A2 19971217; FI 972988 A0 19970714; FI 972988 A 19970911; HK 1009099 A1 19990910; NO 321830 B1 20060710; NO 973261 D0 19970714; NO 973261 L 19970912

DOCDB simple family (application)

AU 4864496 A 19960111; CA 2209892 A 19960111; EP 96904573 A 19960111; FI 972988 A 19970714; HK 98110118 A 19980824; NO 973261 A 19970714